HIV Clinical Trial
Official title:
Toxicity and Pharmacokinetics of Different Rifabutin Doses in HIV-infected Adults and Adolescents Taking Lopinavir / Ritonavir as Second-line Anti-retroviral Therapy (ART) (EARNEST Rifabutin PK Substudy)
- Background and study aims?
Some of the drugs used to treat HIV (anti-retrovirals, or ARVs) can affect the blood levels
of other drugs used to treat TB - called a "drug-drug interaction". The main drug used in
second-line therapy, Aluvia (lopinavir/ritonavir), is one of the drugs that has this effect.
This is why people on second-line ARVs usually cannot use one of the main TB drugs,
"rifampicin", and instead will be prescribed a slightly different drug called "rifabutin",
which is less affected by these drug-drug interactions. Although blood levels of rifabutin
are not as badly affected by Aluvia as blood levels of rifampicin, rifabutin levels in the
blood are still increased a lot by taking Aluvia at the same time. This could lead to higher
levels of side-effects because there is more drug in the body. So in the past doctors have
suggested that instead of taking rifabutin every day with Aluvia, it should only be taken
three times a week, on Mondays, Wednesdays and Fridays. However, in the last 2 years, new
studies have suggested that this three times a week regimen might not be enough and that it
may not completely cure TB. So the purpose of this study is to find out whether taking
rifabutin every day with Aluvia really does lead to more side-effects, and whether taking
rifabutin three times a week with Aluvia really does lead to much lower levels of rifabutin
in the blood.
- Who can participate?
This substudy is specifically for people who are already taking anti-TB drugs in EARNEST, or
who need to start anti-TB drugs whilst they are in the EARNEST trial.
- What does the study involve?
Participants will be selected (by chance, chosen by a computer) to one of the following two
rifabutin groups:
Group 1: Rifabutin (150 mg) taken three times a week on Monday/Wednesday/Friday Group 2:
Rifabutin (150 mg) taken every day On these days, one capsule of rifabutin (150 mg) should
be taken in the morning by mouth.
Participants will be asked to attend clinic 2 and 12 weeks after entering the sub-study then
every 6 weeks until the end of their TB treatment, and then return to their usual EARNEST
follow-up schedule. This is roughly the same visit schedule for people with TB who are
usually seen more frequently than those without TB, whether or not the patients join this
sub-study. The 2 week visit is specifically so the investigators can make sure participants
are doing OK on rifabutin and to check carefully that they don't have any side-effects. At
all these visits (including the day when participants enroll into the substudy) the
investigators will take an extra 10 ml (two teaspoons) of blood to do laboratory tests for
side-effects of rifabutin, and to measure the levels of rifabutin and other ARVs in the
blood - these are called "pharmacokinetic" or "PK" studies. On the day of these visits,
participants should not take their dose of rifabutin until after this blood draw, so the
investigators can measure the lowest amount of drug likely in their blood. Instead,
participants should bring the rifabutin dose to clinic, so that they can take it straight
after the blood draw. At the visit 12 weeks after starting rifabutin, participants will need
to stay in clinic for a second blood draw of ~3 ml (half a teaspoon) around 4 hours after
they take the rifabutin dose immediately after the first blood draw. We use this second
sample to see how quickly rifabutin enters the blood. At this special visit the
investigators will make sure participants are first seen as early as possible, so they don't
have to stay any longer than necessary for the second blood draw to be taken 4 hours later.
After participants have completed their TB treatment they will stay in EARNEST until the end
of the trial (144 weeks on second-line therapy).
- What are the possible benefits and risks of participating?
If participants are allocated to Group 1 (150 mg rifabutin three times a week), there is a
risk that they may have lower levels of rifabutin in your blood and this may be less
effective at treating the TB. However, participants should have fewer side-effects. In
contrast, if participants are allocated to Group 2 (150 mg rifabutin daily), here is a risk
that they may get more side-effects, but the levels of rifabutin in the blood should be more
than high enough to have a good chance of curing the TB. Having blood taken may cause some
discomfort and/or bruising in some people. It is currently impossible to know which
rifabutin regimen would be best and participants may find in years to come that they may or
may not have received the best treatment.
- Where is the study run from?
9 EARNEST sites in Uganda as follows: JCRC Kampala, IDI, San Raphael of St Francis
Hospital (Nsambya), JCRC Mbarara, JCRC Mbale, JCRC Kabale, JCRC Kakira, JCRC Gulu
- When is study starting and how long is it expected to run?
Start 05/03/2012 finish on 31/01/2014
- Who is funding the study? Abbott
Status | Recruiting |
Enrollment | 140 |
Est. completion date | January 2014 |
Est. primary completion date | January 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 12 Years and older |
Eligibility |
Inclusion Criteria: - HIV-1 infected adults/adolescents (12 years and older) receiving boosted protease inhibitor (almost exclusively lopinavir/ritonavir, Aluvia) containing second-line ART within the EARNEST trial - Enrolled with or developing TB during EARNEST trial follow-up - Currently receiving or planning to initiate rifabutin-containing anti-TB treatment (ie no contraindications to rifabutin) - Who provide written informed consent Exclusion Criteria: - Patients who have already reached week 132 in the EARNEST trial at time of TB diagnosis will not be enrolled as practical considerations limit follow up to 12 weeks beyond the completion of the week 144 EARNEST visit - Patients who have less than 10 weeks remaining in their course of TB treatment will not be enrolled as they will not contribute to the main PK evaluation at week 12 (window 10-14 weeks) |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Uganda | JCRC Fort Portal | Fort Portal | |
Uganda | JCRC Gulu | Gulu | |
Uganda | JCRC Kabale | Kabale | |
Uganda | JCRC Kakira | Kakira | |
Uganda | Infectious Diseases Institute (IDI) | Kampala | |
Uganda | JCRC Kampala | Kampala | |
Uganda | San Raphael of St Francis Hospital, Nsambya | Kampala | |
Uganda | JCRC Mbale | Mbale | |
Uganda | JCRC Mbarara | Mbarara |
Lead Sponsor | Collaborator |
---|---|
Justine Boles | Abbott |
Uganda,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Grade 3/4 adverse events | The primary analysis will be the difference in proportions ever experiencing one or more grade 3 or 4 adverse events (AEs) after substudy randomisation, with non-inferiority demonstrated if the upper limit of the 90% confidence interval around the risk difference(Group 2 - Group 1) lies below +20%. | Minimum 24 weeks, maximum 100 weeks | Yes |
Secondary | Rifabutin and its 25-o-desacetyl metabolite pharmacokinetic parameters (from a population PK model) | Population PK models being developed at the University of Capetown for daily and thrice weekly rifabutin dosing will be used to estimate rifabutin PK parameters (time-concentration curve (AUC), trough (Cmin), and apparent oral clearance (CL/F)), which will be compared between groups using geometric means (ttest for the log-transformed values). | 28 weeks | No |
Secondary | Lopinavir/ritonavir pharmacokinetic parameters (from a population PK model) | Population PK models being developed at the University of Capetown for daily and thrice weekly rifabutin dosing will be used to estimate lopinavir and ritonavir PK parameters (time-concentration curve (AUC), trough (Cmin), and apparent oral clearance (CL/F)), which will be compared between groups using geometric means (ttest for the log-transformed values). | 28 weeks | No |
Secondary | Raltegravir pharmacokinetic parameters (from a population PK model) | Population PK models as above. Parameters include time-concentration curve (AUC), trough (Cmin), and apparent oral clearance (CL/F) | 28 weeks | No |
Secondary | Response to TB therapy | Culture positive at 24 weeks or subsequent relapse/recurrence | 24 weeks or at relapse/recurrence (up to maximum 100 weeks) | No |
Secondary | Rifamycin resistance | 24 weeks or at relapse/recurrence (up to maximum 100 weeks) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06162897 -
Case Management Dyad
|
N/A | |
Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
Completed |
NCT02528773 -
Efficacy of ART to Interrupt HIV Transmission Networks
|
||
Active, not recruiting |
NCT05454839 -
Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
|
||
Recruiting |
NCT05322629 -
Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women
|
N/A | |
Completed |
NCT02579135 -
Reducing HIV Risk Among Adolescents: Evaluating Project HEART
|
N/A | |
Active, not recruiting |
NCT01790373 -
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
|
N/A | |
Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
Completed |
NCT04039217 -
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
|
Phase 4 | |
Active, not recruiting |
NCT04519970 -
Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)
|
N/A | |
Completed |
NCT04124536 -
Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
|
N/A | |
Recruiting |
NCT05599581 -
Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health
|
N/A | |
Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
Completed |
NCT02758093 -
Speed of Processing Training in Adults With HIV
|
N/A | |
Completed |
NCT02500446 -
Dolutegravir Impact on Residual Replication
|
Phase 4 | |
Completed |
NCT03805451 -
Life Steps for PrEP for Youth
|
N/A | |
Active, not recruiting |
NCT03902431 -
Translating the ABCS Into HIV Care
|
N/A | |
Completed |
NCT00729391 -
Women-Focused HIV Prevention in the Western Cape
|
Phase 2/Phase 3 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 |